rtA181S mutation in the reverse-transcriptase domain of HBV is associated with adefovir dipivoxil resistance
YANG Jing,LIU Yan,CHEN Rong-juan,XU Zhi-hui,CHEN Li,XIN Shao-jie,LIU Xin-guang,XU Dong-ping
2013-01-01
Abstract:Objective To analyze the association between rtA181S mutation in the reverse-transcriptase(RT) domain of HBV and adefovir dipivoxil(ADV) resistance. Methods Incidence of rtA181S mutation of HBV RT region was screened and analyzed from large samples of chronically HBV-infected patients by direct sequencing. Clonal sequencing was performed and drug- resistance-associated mutations were analyzed from the serum of an ADV-refractory patient with chronic hepatitis B. pGEM-Teasy RT plasmid and pTriEx-HBV(C) plasmid were digested and ligated by the restriction enzyme(XhoⅠ/SphⅠ), and the 1.1-ploid genome length HBV recombinant plasmids harboring wild-type and three kinds of mutants in RT region were constructed. Then the replication-competent constructs were transiently transfected into the HepG2 cells. Five hours post-transfection, new medium containing different concentrations of ADV(0, 0.033, 0.100, 0.330, 1.000, 3.300 μmol/L) was supplemented every other day for 4 days. To analyze the phenotypic characteristics of the HBV mutants under the drug pressure, the supernatant was collected and HBV DNA production was quantitated using real-time PCR. Results A total of 12 000 serum samples of 9830 patients with chronic HBV infection were screened. rtA181S mutation was detected in 46 nucleos(t)ide analogues-treated patients. By contrast, signature ADV- resistance mutations rtN236T and A181V were detected in 653 patients. The rtA181S emerged either alone or in concomitance with other drug-resistance mutations. A follow-up patient developed virological and biochemical breakthrough after 19-month ADV monotherapy. At the time of sampling, rtA181S+N236T was detected by direct sequencing. Clonal sequence analysis of 24 clones showed that there were 11(45.83%) for wild-type, 6(25.00%) for rtN236T, 5(20.83%) for rtA181S, 1(4.16%) for rtA181V, and 1(4.16%) for rtA181S+N236T. The relative viral replication capacity of rtN236T, rtA181S and rtA181S+N236T mutants was 91. 35%, 29.90% and 68.53% that of the wild-type strain, respectively. Phenotypic resistance analysis showed that ADV suscep- tibility of mutants harboring rtN236T, rtA181S and rtA181S +N236T was 1/4.41, 1/3.05, and 1/5.43 that of the wild-type strain. Conclusions rtA181S is an ADV-resistance-associated mutation, which may cause the drug resistance solely or with other mutations in patients with chronic HBV infection. Compared to signature ADV-resistance mutation, rtA181S mutation is less resistant and less frequently detected in ADV-resistance patients.